Faeth Therapeutics (FTH) PAO Josiah Craver Receives Award

What Happened

• Josiah Craver, PAO of Faeth Therapeutics (FTH), was granted a performance-based stock option for 30,824 shares on 2026-07-21. The grant shows an acquisition price of $0 and a reported value of $0 on the Form 4 because this is a derivative award (option), not an immediate stock purchase. This is an award/compensation grant rather than an open-market buy or sell.

Key Details

• Transaction date: 2026-07-21; Form 4 filed 2026-07-23 reporting that transaction.
• Award: performance-based stock option for 30,824 shares; acquisition price $0; reported value $0 (derivative).
• Shares owned after transaction: not stated in the filing.
• Performance conditions (footnote summary): option vests and becomes exercisable only after (i) the average closing price of FTH on Nasdaq over any 30 consecutive calendar days equals or exceeds $70.00 (the "Stock Price Hurdle") and (ii) the first anniversary of the grant date; if the hurdle is not met by the fourth anniversary, the option is forfeited.
• Change in Control (footnote): if a Change in Control occurs before the performance period ends and the per-share consideration ≥ $70.00 (subject to adjustment), the hurdle is deemed met and the option vests immediately prior to the transaction, subject to continued service.
• Filing timeliness: Form 4 filed two days after the grant (2026-07-23 reporting the 2026-07-21 grant), within the normal 2-business-day Form 4 reporting window.

Context

• This grant does not create immediate share ownership or signal a sale/price-taking event; it establishes a contingent right to acquire shares only if specified performance conditions are met.
• Performance-based option grants are common for executive incentives and retention; they become meaningful only if the stock price and service conditions are satisfied.